Results 231 to 240 of about 419,003 (365)

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou   +6 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

open access: yesHepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres   +21 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.

open access: yesJournal of Hepatology, 2018
P. Angeli   +8 more
semanticscholar   +1 more source

Guideline‐directed medical therapy rates in heart failure patients with reduced ejection fraction in a diverse cohort

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Guideline‐directed medical therapy (GDMT) is recommended for all patients with heart failure with reduced ejection fraction (HFrEF). Despite this, little data exist describing GDMT use in diverse, real‐world populations including the use of vasodilators, prescribed primarily to Black populations.
Natalia C. Berry   +4 more
wiley   +1 more source

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

open access: yesHepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole   +12 more
wiley   +1 more source

Stories behind the cover

open access: yesPortal Hypertension & Cirrhosis, 2023
Editorial Office
doaj   +1 more source

State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age

open access: yesESC Heart Failure, EarlyView.
Abstract Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co‐morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging.
Roy Rasalam   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy